Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

5-Amino-1MQ vs. Similar Peptides: Side Effect Comparison

Comparing 5-Amino-1MQ's safety profile to established metabolic compounds provides context for risk assessment. While direct head-to-head studies are unavailable, individual compound profiles offer useful comparisons.[1,2] 5-Amino-1MQ NNMT inhibitor Fatigue (3

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Comparing 5-Amino-1MQ's safety profile to established metabolic compounds provides context for risk assessment. While direct head-to-head studies are unavailable, individual compound profiles offer useful comparisons.[1,2]
  • 5-Amino-1MQ
  • NNMT inhibitor
  • Fatigue (30-40%)
  • 35-45%
  • Unknown
  • Limited human data
  • Semaglutide
  • GLP-1 agonist
  • Nausea (44%)
  • 60-70%
  • <1%
  • FDA-approved, extensive data
  • Tirzepatide
  • GLP-1/GIP agonist
  • Nausea (12-22%)
  • 40-50%
  • Dual mechanism
  • AOD-9604
  • hGH fragment
  • Injection site reactions (15%)
  • <0.1%
  • Topical application available
  • The comparison reveals 5-Amino-1MQ's unique fatigue profile, contrasting with the predominantly gastrointestinal effects seen with GLP-1 receptor agonists. However, the absence of large-scale human trials makes definitive safety comparisons impossible.[2]